[1] Liu WJ, Wu GZ. Convincing the confidence to conquer COVID-19: from epidemiological intervention to laboratory investigation. Biosaf Health 2020;2(4):185 − 6. http://dx.doi.org/10.1016/j.bsheal.2020.11.005CrossRef
[2] Jiang XL, Wang GL, Zhao XN, Yan FH, Yao L, Kou ZQ, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. Nat Commun 2021;12(1):897. http://dx.doi.org/10.1038/s41467-021-21155-xCrossRef
[3] Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020;20(6):355 − 62. http://dx.doi.org/10.1038/s41577-020-0331-4CrossRef
[4] Sun YP, Liu J, Yang M, Gao F, Zhou JF, Kitamura Y, et al. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol 2010;91(4):919 − 30. http://dx.doi.org/10.1099/vir.0.016766-0CrossRef
[5] Liu J, Zhang SH, Tan SG, Yi Y, Wu B, Cao B, et al. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. J Virol 2012;86(24):13281 − 94. http://dx.doi.org/10.1128/JVI.01841-12CrossRef
[6] Zhao M, Liu KF, Luo JJ, Tan SG, Quan CS, Zhang SJ, et al. Heterosubtypic protections against human-infecting avian influenza viruses correlate to biased cross-T-cell responses. mBio 2018;9(4):e01408 − 18. http://dx.doi.org/10.1128/mBio.01408-18CrossRef
[7] Zhang J, Lin H, Ye BW, Zhao M, Zhan JB, Dong SB, et al. One-year sustained cellular and humoral immunities of COVID-19 convalescents. Clin Infect Dis 2021ciab884. http://dx.doi.org/10.1093/cid/ciab884CrossRef
[8] Zhu SY, Liu KF, Chai Y, Wu YN, Lu D, Xiao WL, et al. Divergent peptide presentations of HLA-A*30 alleles revealed by structures with pathogen peptides. Front Immunol 2019;10:1709. http://dx.doi.org/10.3389/fimmu.2019.01709CrossRef
[9] Li X, Liu J, Qi JX, Gao F, Li QR, Li XY, et al. Two distinct conformations of a rinderpest virus epitope presented by bovine major histocompatibility complex class I N*01801: a host strategy to present featured peptides. J Virol 2011;85(12):6038 − 48. http://dx.doi.org/10.1128/JVI.00030-11CrossRef
[10] Lu D, Liu KF, Zhang D, Yue C, Lu Q, Cheng H, et al. Peptide presentation by bat MHC class I provides new insight into the antiviral immunity of bats. PLoS Biol 2019;17(9):e3000436. http://dx.doi.org/10.1371/journal.pbio.3000436CrossRef
[11] Liu WJ, Tan SG, Zhao M, Quan CS, Bi YH, Wu Y, et al. Cross-immunity against avian influenza A(H7N9) virus in the healthy population is affected by antigenicity-dependent substitutions. J Infect Dis 2016;214(12):1937 − 46. http://dx.doi.org/10.1093/infdis/jiw471CrossRef
[12] Zhu LN, Yang PH, Zhao YZ, Zhuang ZK, Wang ZF, Song R, et al. Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity 2020;53(3):685 − 96.e3. http://dx.doi.org/10.1016/j.immuni.2020.07.009CrossRef
[13] Liu J, Wu B, Zhang SH, Tan SG, Sun YP, Chen ZJ, et al. Conserved epitopes dominate cross-CD8+ T-cell responses against influenza A H1N1 virus among Asian populations. Eur J Immunol 2013;43(8):2055 − 69. http://dx.doi.org/10.1002/eji.201343417CrossRef
[14] Liu J, Wu P, Gao F, Qi JX, Kawana-Tachikawa A, Xie J, et al. Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. J Virol 2010;84(22):11849 − 57. http://dx.doi.org/10.1128/JVI.01464-10CrossRef
[15] Liu WJ, Zhao M, Liu KF, Xu K, Wong G, Tan WJ, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res 2017;137:82 − 92. http://dx.doi.org/10.1016/j.antiviral.2016.11.006CrossRef